TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)
Status:
Completed
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This study will look at the safety and effects of combining a new drug called Talimogene
Laherparepvec (T-VEC) with chemotherapy delivered by Isolated Limb Perfusion (ILP). The
investigators want to find out whether these two treatments can be combined safely and
whether T-VEC with ILP is better at treating your cancer than with ILP alone.